<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075291</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0571</org_study_id>
    <nct_id>NCT05075291</nct_id>
  </id_info>
  <brief_title>Suicide Attempts and Tramadol : a Case Report</brief_title>
  <official_title>Repeated Suicide Attempts in a Patient Suffering From Addiction to Tramadol: a Case Report</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, over the last years the use weak opioid analgesics decreased́, whereas that of&#xD;
      strong opioid analgesics (OFMA). Hospitalizations for opioid overdose increased́ by 128% from&#xD;
      2000 to 2015, and deaths related to prescribed opioid overdose increased significantly, by&#xD;
      161%, from 2000 to 2014.In addition, recent studies suggest a link between opioid system&#xD;
      dysfunction and suicidal behavior.&#xD;
&#xD;
      In parallel, studies are emerging showing the potential interest of using Tramadol as an&#xD;
      antidepressant. Indeed, this opiate analgesic also acts on the serotonergic and dopaminergic&#xD;
      systems, and would have an antidepressant effect.Thus, the investigators can legitimately&#xD;
      wonder whether the use of Tramadol as an antidepressant might not pose a problem in patients&#xD;
      at risk of suicide.&#xD;
&#xD;
      This study aims to describe a clinical case of a patient hospitalized in the Department of&#xD;
      Psychiatric Emergency and Post-Emergency (Montpellier University Hospital) who developed a&#xD;
      severe addiction to Tramadol (consumption up to 5 times the maximum recommended dose per day)&#xD;
      and evaluate whether this may have increased her suicidal risk, in order to warn prescribers&#xD;
      about the suicidal risk of Tramadol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lifetime suicidal events</measure>
    <time_frame>day 1</time_frame>
    <description>Occurrence of suicidal events (actuel, interrupted and aborted or self-aborted suicide attempts) based on the patient medical records.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depressive symptomatology</measure>
    <time_frame>day 1</time_frame>
    <description>Depressive symptomatology assessed with the Montgomery Asberg Depression Rating Scale (MADRS). The total score ranges from 0 to 60 :&#xD;
scores between 0 and 6 : no depression,&#xD;
scores between 7 and 19 : mild depression,&#xD;
scores between 20 and 34 : moderate depression&#xD;
scores above 34 : severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal ideation</measure>
    <time_frame>day 1</time_frame>
    <description>Suicidal thoughts assessed with the Columbia Suicide Severity Scale (C-SSRS). The suicidal ideation severity subscale ranges from 1 to 5 (with higher number indicating more severe ideation). The intensity of ideation subscale includes 5 questions each one ranging from 1 to 5 (with higher number indicating more intense ideation). The suicidal behavior subscale includes 4 yes/no questions. The suicidal behavior lethality subscale inquires about the level of actual or potential medical damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological pain</measure>
    <time_frame>day 1</time_frame>
    <description>Psychological pain assessed with a Likert scale : Strongly disagree, Disagree, Neutral, Agree, Strongly agree</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>day 1</time_frame>
    <description>Anxiety level assessed with a Likert scale : Strongly disagree, Disagree, Neutral, Agree, Strongly agree</description>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Suicide, Attempted</condition>
  <condition>Addiction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A single patient with multiple suicide attempts related to her addiction to Tramadol.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Multiple suicide attempts&#xD;
&#xD;
          -  Tramadol addiction&#xD;
&#xD;
        NA : patient case report&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bénédicte NOBILE, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suicide</keyword>
  <keyword>Addiction</keyword>
  <keyword>Opioids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Suicide, Attempted</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

